Atormac
briv
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 11505  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (979 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 » Subjects and Methods
 » Results
 » Discussion
 » Conclusion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed538    
    Printed4    
    Emailed0    
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
ORIGINAL ARTICLE
Year : 2021  |  Volume : 69  |  Issue : 2  |  Page : 369-375

Utility of Serial Nerve Conduction Studies in the Electrodiagnosis of Guillain–Barre Syndrome


1 Neurology Unit, Department of Neurological Sciences, Christian Medical College, Vellore, Tamil Nadu, India
2 The Brunei Neuroscience Stroke and Rehabilitation Centre, India

Date of Submission20-Feb-2020
Date of Decision22-Jun-2020
Date of Acceptance12-Feb-2021
Date of Web Publication24-Apr-2021

Correspondence Address:
Mathew Alexander
The Brunei Neuroscience Stroke and Rehabilitation Centre, Brunei; Former Head of Neurology, Christian Medical College Vellore - 632 004, Tamil Nadu, India
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.314529

Rights and Permissions

 » Abstract 


Background: Guillain–Barre syndrome can be electrophysiologically classified into demyelinating and axonal subtypes and nerve conduction studies remain the mainstay in electrodiagnosis. Accurate electrodiagnosis has both therapeutic and prognostic significance and different criteria sets have been proposed for classification.
Objectives: To electrophysiologically classify GBS patients into AIDP and axonal subtypes according to various published criteria (Cornblath, 1990: Hadden, 1998, Rajabally, 2015), investigate if serial NCS changes the classification, and to identify additional parameters which may support the electrodiagnosis.
Materials and Methods: In a retrospective study, we included all patients aged 15 to 80 years, admitted with a diagnosis of GBS between August 2015 and July 2017, who had at least two serial NCS. The various published criteria were applied to the two serial NCS and subtype classification along with diagnostic shifts on serial NCS were ascertained.
Results: At the first test, the established criteria gave a yield of 45.2% to 71% for AIDP, while 29% to 54.8% of patients were classified as axonal GBS. In the second study, there was a change in electrodiagnosis, ranging from 9.6% to 16.1%. The resolution of reversible conduction failure and misclassification of subtypes were the major reason for diagnostic shifts. Sural sparing pattern, facial nerve dysfunction, abnormal blink reflex, and phrenic nerve dysfunction were more common in AIDP.
Conclusions: Serial nerve conduction studies allow an accurate electrodiagnosis of GBS subtypes, which has both therapeutic and prognostic implications. Also, the use of additional parameters such as blink reflex facial and phrenic nerve conduction may supplement routine NCS.


Keywords: GBS, reversible conduction failure, serial nerve conduction studies
Key Message: Serial nerve conduction studies are mandatory for an accurate electrodiagnosis of GBS


How to cite this article:
Mani AM, Prabhakar AT, Alexander P T, Nair A, Vijayaraghavan A, Shaikh A, Benjamin R, Sivadasan A, Mathew V, Aaron S, Alexander M. Utility of Serial Nerve Conduction Studies in the Electrodiagnosis of Guillain–Barre Syndrome. Neurol India 2021;69:369-75

How to cite this URL:
Mani AM, Prabhakar AT, Alexander P T, Nair A, Vijayaraghavan A, Shaikh A, Benjamin R, Sivadasan A, Mathew V, Aaron S, Alexander M. Utility of Serial Nerve Conduction Studies in the Electrodiagnosis of Guillain–Barre Syndrome. Neurol India [serial online] 2021 [cited 2021 May 15];69:369-75. Available from: https://www.neurologyindia.com/text.asp?2021/69/2/369/314529




Guillain–Barre syndrome (GBS) is the most common cause of acute flaccid paralysis worldwide. It can be classified electrophysiologically into demyelinating and axonal subtypes. Acute inflammatory demyelinating polyneuropathy (AIDP) is the demyelinating subtype, while acute motor axonal (AMAN) and acute motor-sensory axonal neuropathy (AMSAN) are the axonal subtypes. It is difficult to differentiate between them clinically and nerve conduction studies (NCS) can play an important role.

Determining the electrophysiological subtype is useful as it can give insights into the underlying pathophysiology.[1] This has both therapeutic and prognostic significance. Various electrodiagnostic criteria sets have been proposed to differentiate between the demyelinating and axonal subtypes.[2–4]

There has been a controversial debate[5] as to whether the subtypes can be diagnosed accurately based on a single study, with one group of authors advocating a “serial studies approach”[6–8] and another group rebutting this and advocating a “one study approach”.[4],[9],[10]

There is a lack of studies universally as well as from India looking at the utility of serial NCS in the management of patients with GBS. Hence this retrospective analysis was done to determine if serial NCS changes the electrodiagnostic classification, and to identify additional parameters that may support the electrodiagnosis in early stages.


 » Subjects and Methods Top


Patients

We retrospectively reviewed our institutional database of adult patients aged 15 to 80 years, admitted with a diagnosis of GBS between August 2015 and July 2017 at Christian Medical College, Vellore. Patients who had at least two serial electrophysiological recordings were selected. The study variables were retrieved from a prospectively maintained database.

Electrophysiology

All the patients had NCS done on eight motor and eight sensory nerves using conventional techniques. Parameters measured included: distal motor latency (DML), sensory latencies, motor and sensory conduction velocities (CV), compound action potentials (CMAP), F-wave latencies (FL), and sensory action potentials (SNAPs). The skin temperature was maintained over 32°C. The value of each variable was compared with the upper and lower limits of normal for our laboratory. For DML, motor CV, F wave latency, CMAP, and SNAP amplitudes, the upper and lower limits of normal were defined as the mean ± 2.5 SD of control values of our laboratory. Sural sparing pattern was defined as sural SNAP >15microV and ulnar SNAP <2.5 SD of LLN. Facial nerve conduction, blink reflex, phrenic nerve conduction, and electromyography data were analyzed if available. Facial nerve dysfunction was defined as facial CMAP less than 4 mV. Abnormal blink reflex was defined as marked delayed or absence of all potentials of the blink response. Phrenic nerve dysfunction was defined as either phrenic CMAP <0.4 mV or phrenic latency >9 ms.

Electrodiagnostic criteria

We applied the various published criteria [Table 1] to the two sets of NCS and classified them into AIDP and axonal GBS. Temporal dispersion (TD) was not included for classification as we did not have the required data. Patients who did not satisfy the criteria for AIDP or axonal GBS were classified as equivocal. We also established the diagnostic shifts for each set of criteria, as a result of serial NCS.
Table 1: Electrodiagnostic criteria for GBS

Click here to view


Anti-ganglioside antibody testing

Serum anti-ganglioside antibodies were tested in serum by ELISA. Testing was done for GM1, GD1a, GD1b, GT1a, and GQ1b.

Statistical analysis

Patients were grouped according to electrodiagnosis at first study, electrodiagnosis at the second study, and anti-ganglioside antibody status. The statistical analysis was performed using IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp. Descriptive analysis was performed using the Chi-square test. Statistical significance was taken to be at the two-tailed 0.05 level.


 » Results Top


There were a total of 40 patients with GBS, out of which 31 patients had serial NCS. There were 21 males and 10 females. The mean age of the cohort was 37.8 (SD: 17.8) years. The mean interval between the onsets of illness to first NCS was 1.6 (SD: 0.7, range 1-3) weeks and the second NCS was 3.5 (SD: 1.5, range 2-8) weeks. The mean interval between the serial NCS was 1.9 (range 1-6) weeks. Twenty-three patients (74%) were treated with plasma exchange while 8 patients (26%) were treated with IVIG. The clinical profile, anti-ganglioside antibody status, the requirement of assisted ventilation, and electrodiagnosis on serial NCS are shown in [Table 2].
Table 2: Clinical profile, anti-ganglioside antibody status and electrodiagnosis on serial NCS

Click here to view


Electrodiagnostic shifts on serial NCS

The electrodiagnosis of GBS on serial NCS according to the various published criteria are given in [Table 3]. According to Cornblath, Hadden, and Rajabally criteria, 5 patients (16.1%), 3 patients (9.6%), and 5 patients (16.1%) respectively changed classification. Out of the five patients that changed classification from AIDP to axonal/equivocal [Table 4], four were due to the resolution of reversible conduction failure (RCF) [Figure 1]. All the six patients that changed classification from axonal to AIDP/equivocal [Table 5] were due to misclassification. Four out of the six patients were misclassified as AIDP on the second study.
Table 3: Serial NCS in GBS and change in electrodiagnosis

Click here to view
Table 4: Change in electrodiagnosis from AIDP to axonal/equivocal

Click here to view
Figure 1: Reversible conduction failure on Serial NCS of the right peroneal nerve in a patient with axonal GBS and antiganglioside antibodies. The serial NCS were done on 4th day (a), 13th day (b) and 24th day (c)

Click here to view
Table 5: Change in electrodiagnosis from axonal to AIDP/equivocal

Click here to view


Additional parameters supporting electrodiagnosis

The relation between the GBS subtype and the other electrophysiological parameters were studied at the first NCS [Table 6]. Among them, the presence of a sural sparing pattern, facial nerve dysfunction, abnormal blink reflex, and phrenic nerve dysfunction was found to be statistically significant. The sural sparing pattern was more common in AIDP, ranging from 22.7% to 35.7% of patients with AIDP. It was statistically significant for Rajabally criteria. Facial nerve dysfunction was also more common in AIDP, ranging from 42.8% to 69.2% of patients. It was statistically significant for all three criteria. Abnormal blink reflex was also more common in AIDP, ranging from 45% to 75% of patients, respectively. It was statistically significant for Cornblath and Rajabally criteria. Three patients had an abnormal blink reflex with normal facial conductions. Phrenic nerve dysfunction was also more common in AIDP, ranging from 36.3% to 57.1% of patients. It was also statistically significant for Rajabally criteria.
Table 6: Parameters supporting electrodiagnosis at first NCS

Click here to view


Relations between GBS subtype and anti-ganglioside antibodies

Anti-ganglioside antibodies were tested in 26 out of the 31 patients. They were present in 46.1% of patients (12/26). Six patients were positive for the single type of anti-ganglioside antibody while the remaining six patients showed positivity to two types of anti-ganglioside antibodies. Antibody to GM1 was the most common subtype. They were more common in axonal GBS, present in 56.2%, 50%, and 53.8% of patients according to Cornblath, Hadden, and Rajabally criteria respectively at the second electrodiagnostic study. They were present in 2 patients with a shift in electrodiagnosis from AIDP and in 3 patients with a shift from axonal.


 » Discussion Top


Accurate electrodiagnosis of GBS is important as it offers insight into the underlying pathophysiology. In axonal GBS, there is nodal and paranodal involvement due to antibody-mediated attack and complement activation resulting in conduction failure. This can manifest as a conduction block, conduction slowing, and isolated F wave absence.[11] Classically, this results in axonal degeneration.[12] However, in some patients, conduction failure resolves and axonal degeneration does not occur.[13–15] Thus, there are two possible patterns of evolution which can be seen in axonal GBS. The common pattern is a reduction of distal CMAP amplitudes which is due to axonal degeneration. In the other pattern, a rapid improvement in CMAP amplitudes and CV is seen due to the resolution of nodal conduction failure.[11] Both patterns are not associated with an increase in TD. AIDP is characterized by segmental demyelination in both motor and sensory nerves, resulting in abnormalities of the F and H responses, conduction blocks, abnormal temporal dispersion.[16] As the process of remyelination occurs, there is a slowing of CV with persistently increased TD. There has been evidence of complement activation leading to myelin disruption as well as secondary axonal degeneration in AIDP as well. Thus, the pathophysiology of GBS is dynamic and serial studies may allow a more accurate diagnosis of subtypes.

Considering the recent advances in the field of both pathophysiology and treatment of GBS, an early accurate electrodiagnosis becomes paramount in the management. IVIG could potentially be more effective in settings where there is more complement-mediated damage There are some preliminary reports which have suggested that for IVIG is better than PLEX for patients with AMAN.[17] There is also a need to identify early the subtypes with a potentially refractory disease given the options of considering IVIG and eculizumab which could have a major impact on long-term morbidity.[18] This emphasizes the importance of an early accurate electrodiagnosis in guiding early targeted treatment.

The patterns of recovery in axonal GBS and AIDP are also different, with axonal GBS generally taking much longer than AIDP.[19] Hence, accurate electrodiagnosis of GBS has both therapeutic and prognostic implications.

The frequency of subtypes of GBS has substantial variability in different series. This may be due to differences in triggering factors, genetic susceptibility, and different antecedent infections. It can also be due to the different electrodiagnostic criteria used and whether it was based on a single study or serial NCS. In North America and Europe, AIDP is more common, comprising up to 90%.[3]

In India, using the Cornblath criteria on a single NCS, Alexander et al.[20] found 55.7% of patients to have AIDP while Kalita et al.[21] found that 39.2% of patients had AIDP. Using the Cornblath criteria on serial NCS, we found that 45.2% had AIDP on the first NCS. On the second NCS, the number of patients with AIDP was reduced to 41.9%. Using Hadden's criteria, Uncini et al.[22] found 67% of patients to have AIDP, 18% to have axonal GBS, and 15% to have equivocal electrodiagnosis on the first NCS. On the second NCS, the number of patients with AIDP and equivocal electrodiagnosis reduced to 58% and 4% respectively, while the number of patients with axonal GBS increased to 38%. Using Hadden's criteria, we found that 71% had AIDP and 21% had axonal GBS on the first NCS. On the second NCS, the number of patients with AIDP reduced to 64.5%, while the number of patients with axonal GBS remained the same at 21% and 6.5% had an equivocal electrodiagnosis.

In our study, 16.1%, 9.6%, and 16.1% of patients changed classification on serial NCS, using, Cornblath, Hadden, and Rajabally criteria, respectively. Uncini et al.[22] found that 23.6% of patients changed subtype, using Hadden's criteria and the majority of the shifts were from AIDP and equivocal groups to axonal GBS. This was mainly due to the recognition of RCF by serial NCS. All patients who shifted to the axonal group also had anti-ganglioside antibodies. In our study, there were shifts in both directions. Historically, there has been no gold standard for GBS subtypes diagnosis and the final diagnosis can be considered as the reference diagnosis, as it was reached considering the whole electrophysiological history of the patient.[23] For practical purposes, Uncini and Kuwabara have suggested that at the first study Rajabally criteria sets can be employed for an indicative subtype diagnosis. This is an observation from our study as well considering the comprehensiveness of Rajabally criteria.[23]

The major reason for shifts from AIDP to axonal GBS was the resolution of RCF on serial NCS.[13–15] A single NCS can't distinguish between demyelinating conduction block and RCF and can misclassify patients with axonal GBS as having AIDP. RCF is an a posteriori diagnosis and can be identified only on serial NCS [Figure 1]. Electrodiagnostic criteria for RCF has been published recently.[7]

The major reason for shifts from axonal GBS to AIDP was the misclassification of subtypes due to inherent flaws in the criteria. With the current criteria, there is a tendency for underdiagnoses of axonal GBS, primarily due to misclassification as AIDP.[14],[22] This is because both demyelination and nodal conduction failure can lead to prolonged DML, decreased CV, and conduction block. Thus, in the early stages of GBS, the distinction between demyelinating and axonal subtypes can be difficult in some patients. In our study, misclassification in these cases occurred probably because the second study was done earlier done at an average interval of 1.9 (range 1-6) weeks after the first study. Traditionally, the first NCS has been done at around 2 weeks after disease onset and the second study at a variable interval after the same. Uncini and Kuwabara[11] have suggested at least two NCS in the first 4–6 weeks of the disease. Shahrizaila et al.[8] have suggested that performing NCS at two time intervals, 1st NCS at admission and 2nd NCS at an interval of 3–8 weeks after disease onset can make an accurate electrodiagnosis of GBS.

A sural sparing pattern is seen only in AIDP and is a specific electrodiagnostic feature that can discriminate AIDP from axonal GBS. Derksen et al.[24] studied 73 patients with GBS and 38 patients with GBS mimics and found that the most specific finding suggestive of AIDP was the sural sparing pattern. In our study also, we found that the sural sparing pattern was more common in AIDP.

The literature concerning the utility of blink reflex, facial nerve, and phrenic nerve conductions to differentiate between AIDP and axonal subtype is scant. Our study has also identified that the presence of facial nerve dysfunction, abnormal blink reflex, and phrenic nerve dysfunction helps to differentiate AIDP from axonal subtype in the early stages. Compared with AIDP, patients with axonal GBS have less frequent cranial-nerve involvement.[25] Vucic et al.[26] analyzed blink responses in 38 patients with AIDP within ten days of symptom onset and found abnormalities in 51% of patients, out of which 69% clinically exhibited facial weakness. They found that blink reflexes can be abnormal in some AIDP patients with clinically normal facial strength. Hence blink reflex should be done in all patients with suspected GBS. In our study, we found that facial dysfunction and abnormal blink reflex were more common in AIDP. This is probably due to demyelination in the facial and trigeminal nerves and can help to differentiate AIDP from axonal subtype in the early stages. In a study by Gourie-Devi and Ganapathy,[27] phrenic nerve conduction abnormalities were observed in 64.3% of patients with GBS. Sen et al.[28] studied phrenic nerve conduction in 64 patients with AIDP and found abnormal phrenic nerve conductions in 65.62% of patients. In our study also, abnormal phrenic nerve conduction was found to be more common in AIDP than axonal GBS. These parameters potentially have a greater relevance even compared to the conventionally described “sural sparing pattern” which was found only in a relatively smaller number. These indicate the presence of subclinical dysfunction in a non-length dependent pattern as described in demyelinating neuropathies.

Anti-ganglioside antibodies have an important role in the immunopathogenesis of GBS and can be directed against myelin or the axon.[29] The most common antibodies that are identified are against GM1, GD1a, GD1b, GT1a, and GQ1b gangliosides. They are more common in axonal GBS than AIDP.[30] Naik et al.[31] tested 73 patients with GBS for anti-ganglioside antibodies and found that they were present in 45.6% with AIDP and 50% with axonal subtype. In our study, they were present in 46.1% with AIDP and 53.3% with axonal subtype. Anti-GT1b antibody was the most common antibody in their study, while in our study, anti-GM1 was the most common.

The strengths of the study include the incorporation of a standard protocol comprising NCS from all the four limbs with blink reflex, facial and phrenic conductions. All the studies were performed under the supervision of a core group of senior neurologists. Limitation of this study was the small sample size and retrospective design. However, it has given a good insight into the utility of serial NCS as the electrodiagnostic studies were comprehensive.


 » Conclusion Top


Thus, serial nerve conduction studies are mandatory for an accurate electrodiagnosis of GBS subtypes, which has both therapeutic and prognostic implications. Also, the use of additional parameters such as blink reflex, facial and phrenic nerve conduction, and anti-ganglioside antibodies may supplement routine NCS.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Shahrizaila N, Goh KJ, Kokubun N, Abdullah S, Yuki N. Serial nerve conduction studies provide insight into the pathophysiology of Guillain-Barré and Fisher syndromes. J Neurol Sci 2011;309:26–30.  Back to cited text no. 1
    
2.
Cornblath DR. Electrophysiology in Guillain-Barré syndrome. Ann Neurol 1990;27(Suppl):S17-20.  Back to cited text no. 2
    
3.
Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: Clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré syndrome trial group. Ann Neurol 1998;44:780–8.  Back to cited text no. 3
    
4.
Rajabally YA, Durand M-C, Mitchell J, Orlikowski D, Nicolas G. Electrophysiological diagnosis of Guillain–Barré syndrome subtype: Could a single study suffice? J Neurol Neurosurg Psychiatry 2015;86:115–9.  Back to cited text no. 4
    
5.
Uncini A, Zappasodi F, Notturno F. Electrodiagnosis of GBS subtypes by a single study: Not yet the squaring of the circle. J Neurol Neurosurg Psychiatry 2015;86:5–8.  Back to cited text no. 5
    
6.
Uncini A, Ippoliti L, Shahrizaila N, Sekiguchi Y, Kuwabara S. Optimizing the electrodiagnostic accuracy in Guillain-Barré syndrome subtypes: Criteria sets and sparse linear discriminant analysis. Clin Neurophysiol 2017;128:1176–83.  Back to cited text no. 6
    
7.
Chan Y-C, Punzalan-Sotelo AM, Kannan TA, Shahrizaila N, Umapathi T, Goh EJH, et al. Electrodiagnosis of reversible conduction failure in Guillain-Barré syndrome. Muscle Nerve 2017;56:919–24.  Back to cited text no. 7
    
8.
Shahrizaila N, Goh KJ, Abdullah S, Kuppusamy R, Yuki N. Two sets of nerve conduction studies may suffice in reaching a reliable electrodiagnosis in Guillain–Barré syndrome. Clin Neurophysiol 2013;124:1456–9.  Back to cited text no. 8
    
9.
Ibrahim J, Grapperon A-M, Manfredonia F, van den Bergh PY, Attarian S, Rajabally YA. Serial electrophysiology in Guillain-Barré syndrome: A retrospective cohort and case-by-case multicentre analysis. Acta Neurol Scand 2018;137:335–40.  Back to cited text no. 9
    
10.
Van den Bergh PYK, Piéret F, Woodard JL, Attarian S, Grapperon A-M, Nicolas G, et al. Guillain-Barré syndrome subtype diagnosis: A prospective multicentric European study: GBS subtype diagnosis. Muscle Nerve 2018;58:23–8.  Back to cited text no. 10
    
11.
Uncini A, Kuwabara S. Electrodiagnostic criteria for Guillain–Barrè syndrome: A critical revision and the need for an update. Clin Neurophysiol 2012;123:1487–95.  Back to cited text no. 11
    
12.
McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, et al. Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333–42.  Back to cited text no. 12
    
13.
Capasso M, Caporale CM, Pomilio F, Gandolfi P, Lugaresi A, Uncini A. Acute motor conduction block neuropathy Another Guillain-Barré syndrome variant. Neurology 2003;61:617–22.  Back to cited text no. 13
    
14.
Kokubun N, Nishibayashi M, Uncini A, Odaka M, Hirata K, Yuki N. Conduction block in acute motor axonal neuropathy. Brain 2010;133:2897–908.  Back to cited text no. 14
    
15.
Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 1998;44:202–8.  Back to cited text no. 15
    
16.
Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 1969;48:173–215.  Back to cited text no. 16
    
17.
Kuwabara S, Mori M, Ogawara K, Hattori T, Oda S, Koga M, et al. Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody. Muscle Nerve 2001;24:54–8.  Back to cited text no. 17
    
18.
Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, et al. Safety and efficacy of eculizumab in Guillain-Barré syndrome: A multicentre, double-blind, randomised phase 2 trial. Lancet Neurol 2018;17:519–29.  Back to cited text no. 18
    
19.
Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain-Barré syndromes. Neurology 2003;61:471–4.  Back to cited text no. 19
    
20.
Alexander M, Aaron S, Mathew V, Prabhakar A, Thomas M, Patil A. Utility of neurophysiological criteria in Guillain Barré syndrome: Subtype spectrum from a tertiary referral hospital in India. Neurol India 2011;59:722-6.  Back to cited text no. 20
[PUBMED]  [Full text]  
21.
Kalita J, Misra UK, Das M. Neurophysiological criteria in the diagnosis of different clinical types of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2008;79:289–93.  Back to cited text no. 21
    
22.
Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electrodiagnosis of Guillain-Barre syndrome subtypes. J Neurol Neurosurg Psychiatry 2010;81:1157–63.  Back to cited text no. 22
    
23.
Uncini A, Kuwabara S. The electrodiagnosis of Guillain-Barré syndrome subtypes: Where do we stand? Clin Neurophysiol 2018;129:2586–93.  Back to cited text no. 23
    
24.
Derksen A, Ritter C, Athar P, Kieseier BC, Mancias P, Hartung HP, et al. Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics: Sural Sparing in GBS. Muscle Nerve 2014;50:780–4.  Back to cited text no. 24
    
25.
Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: Concepts and controversies. Lancet Neurol 2013;12:1180–8.  Back to cited text no. 25
    
26.
Vucic S, Cairns KD, Black KR, Tick Chong PS, Cros D. Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin Neurophysiol 2004;115:2329–35.  Back to cited text no. 26
    
27.
Gourie-Devi M, Ganapathy GR. Phrenic nerve conduction time in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1985;48:245–9.  Back to cited text no. 27
    
28.
Sen BK, Pandit A. Phrenic nerve conduction study in the early stage of Guillain–Barre syndrome as a predictor of respiratory failure. Ann Indian Acad Neurol 2018;21:5.  Back to cited text no. 28
[PUBMED]  [Full text]  
29.
Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I. Muscle Nerve 1995;18:137–53.  Back to cited text no. 29
    
30.
Sekiguchi Y, Uncini A, Yuki N, Misawa S, Notturno F, Nasu S, et al. Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: A Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 2012;83:23–8.  Back to cited text no. 30
    
31.
Naik GS, Meena AK, Reddy BAK, Mridula RK, Jabeen SA, Borgohain R. Anti-ganglioside antibodies profile in Guillain-Barré syndrome: Correlation with clinical features, electrophysiological pattern, and outcome. Neurol India 2017;65:1001–5.  Back to cited text no. 31
[PUBMED]  [Full text]  


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow